tiprankstipranks
Advertisement
Advertisement
Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug
PremiumThe FlyUpstream Bio to present new data from Phase 2 Vibrant trial of Verekitug
1M ago
3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
Premium
Market News
3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
2M ago
Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward
Premium
Ratings
Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward
2M ago
Upstream Bio Launches $150 Million At-The-Market Program
PremiumCompany AnnouncementsUpstream Bio Launches $150 Million At-The-Market Program
2M ago
Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors
Premium
Ratings
Upstream Bio Initiated at Buy: Verekitug’s Quarterly Dosing Strategy Positions It for Potential Best-in-Class Efficacy vs. TSLP Competitors
2M ago
Verekitug’s Differentiated Long-Interval Dosing and Late-Stage Pipeline Position It as a Potential Respiratory Blockbuster
Premium
Ratings
Verekitug’s Differentiated Long-Interval Dosing and Late-Stage Pipeline Position It as a Potential Respiratory Blockbuster
2M ago
Upstream Bio announces verekitug met the primary endpoint
PremiumThe FlyUpstream Bio announces verekitug met the primary endpoint
3M ago
XBI vs. IBB: Which Biotech ETF do Analysts Prefer in 2026?
Premium
Market News
XBI vs. IBB: Which Biotech ETF do Analysts Prefer in 2026?
3M ago
Midday Fly By: January payrolls jump, Ford reports mixed Q4
Premium
The Fly
Midday Fly By: January payrolls jump, Ford reports mixed Q4
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100